Up up up!!!_老虎社区_美港股上老虎

pseudomeow
2021-06-17

Up up up!!!

Altimmune, Inc. (ALT) Soars 16.5%: Is Further Upside Left in the Stock?

Altimmune, Inc. ALT shares soared 16.5% in the last trading session to close at $16.46. The move was

Altimmune, Inc. (ALT) Soars 16.5%: Is Further Upside Left in the Stock?

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":161219517,"tweetId":"161219517","gmtCreate":1623928179339,"gmtModify":1634025776329,"author":{"id":3574924039602922,"idStr":"3574924039602922","authorId":3574924039602922,"authorIdStr":"3574924039602922","name":"pseudomeow","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Up up up!!!</p></body></html>","htmlText":"<html><head></head><body><p>Up up up!!!</p></body></html>","text":"Up up up!!!","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/161219517","repostId":2144717905,"repostType":2,"repost":{"id":"2144717905","kind":"news","pubTimestamp":1623906905,"share":"https://www.laohu8.com/m/news/2144717905?lang=&edition=full","pubTime":"2021-06-17 13:15","market":"us","language":"en","title":"Altimmune, Inc. (ALT) Soars 16.5%: Is Further Upside Left in the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2144717905","media":"Zacks","summary":"Altimmune, Inc. ALT shares soared 16.5% in the last trading session to close at $16.46. The move was","content":"<html><body><p><a href=\"https://laohu8.com/S/ALT\">Altimmune, Inc.</a> ALT shares soared 16.5% in the last trading session to close at $16.46. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.4% gain over the past four weeks.</p>\n<p>Encouraging interim data from an early-stage weight loss study on its GLP-1/glucagon dual receptor agonist candidate, ALT-801, drove share prices on Wednesday. The company has several other pipeline candidates, including COVID-19 vaccine and therapeutic candidates. Positive clinical data will drive shares prices further high.</p>\n<p>This company is expected to post quarterly loss of $0.26 per share in its upcoming report, which represents a year-over-year change of +72.3%. Revenues are expected to be $3.84 million, up 432.9% from the year-ago quarter.</p>\n<p>While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.</p>\n<p>For Altimmune, Inc., the consensus EPS estimate for the quarter has been revised 25.7% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on ALT going forward to see if this recent jump can turn into more strength down the road.</p>\n<p>The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here &gt;&gt;&gt;&gt;</p>\n<br/>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n<br/> \n<br/>\nAltimmune, Inc. (ALT) : Free Stock Analysis Report\n<br/> \n<br/>\nTo read this article on Zacks.com click here.\n<br/> \n<br/>\nZacks Investment Research</body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Altimmune, Inc. (ALT) Soars 16.5%: Is Further Upside Left in the Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAltimmune, Inc. (ALT) Soars 16.5%: Is Further Upside Left in the Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 13:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/altimmune-inc-alt-soars-16-051505879.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Altimmune, Inc. ALT shares soared 16.5% in the last trading session to close at $16.46. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...</p>\n\n<a href=\"https://finance.yahoo.com/news/altimmune-inc-alt-soars-16-051505879.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/1dxLXSY5A2hCscEl8bQjIA--~B/aD05MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/p7mMbEOF_0HXQZ7ayoNiSw--~B/aD05MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b37fb2516d615eeca7b35dab54b82078","relate_stocks":{"TERN":"Terns Pharmaceuticals, Inc.","ALT":"Altimmune, Inc.","CRCT":"Cricut, Inc."},"source_url":"https://finance.yahoo.com/news/altimmune-inc-alt-soars-16-051505879.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2144717905","content_text":"Altimmune, Inc. ALT shares soared 16.5% in the last trading session to close at $16.46. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.4% gain over the past four weeks.\nEncouraging interim data from an early-stage weight loss study on its GLP-1/glucagon dual receptor agonist candidate, ALT-801, drove share prices on Wednesday. The company has several other pipeline candidates, including COVID-19 vaccine and therapeutic candidates. Positive clinical data will drive shares prices further high.\nThis company is expected to post quarterly loss of $0.26 per share in its upcoming report, which represents a year-over-year change of +72.3%. Revenues are expected to be $3.84 million, up 432.9% from the year-ago quarter.\nWhile earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.\nFor Altimmune, Inc., the consensus EPS estimate for the quarter has been revised 25.7% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on ALT going forward to see if this recent jump can turn into more strength down the road.\nThe stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n \n\nAltimmune, Inc. (ALT) : Free Stock Analysis Report\n \n\nTo read this article on Zacks.com click here.\n \n\nZacks Investment Research","news_type":1},"isVote":1,"tweetType":1,"viewCount":366,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":9,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}